Modifying Disease Course in Alzheimer's Disease

Slides:

Advertisements

Similar presentations

Alzheimer’s Disease Landscape

Advertisements

How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral.

Alzheimer’s Society, UK Our research programme

Copyright © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 33 Delirium and Dementia.

1 From Cause to Movement Shaping a World Without Alzheimer’s Through Advocacy, Volunteerism, Referral and Science Ian Kremer, Esq. Advocacy & Outreach.

Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.

ALZHIEMERS DISEASE IN UK ‘’The Dementia Time bomb’’ By VISHAL ZAVERI AND ORE AJAI.

Alzheimer’s Disease Today and Tomorrow First case reported in 1906 Reported by Alois Alzheimer Patient Augusta D. first treated at 46 years old Paranoia,

Alzheimer's disease 蕭尚益丁唯洋蔡欣容. Outline introductionDisease mechanismPreventConclusion.

The clinical research of early diagnosis and ultimately the treatment of Alzheimer’s disease 許一仁董冠廷詹鎮遠陳柏廷.

Update and Thank you to participants Bradley Hyman MD PhD Director, Mass ADRC ViceChair, Neurology, Massachusetts General Hospital.

Attaran D, Mashhad university of medical sciences.

Multimodal Management of Opioid-Induced Constipation

The Patient Experience With Systemic Lupus Erythematosus

Volume 2, Issue 1, Pages (January 2016)

Imaging AD Progression Amyloid Imaging Agents.

Diabetic Dyslipidemia in Practice

Silent No More:.

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

The Clinical Enigma of Cardiogenic Shock

Dry AMD and GA: The Present and Future

Best Practices in Huntington Disease

What Predicts Disability Progression in Multiple Sclerosis?

Epilepsy Treatment Across the Spectrum

Patient 1: 53-Year-Old Man With CVD Risk Factors

Hunter Syndrome: Why We Need to Diagnose and Treat Early

Select Topics in Cardiovascular Medicine

Early Dementia Distinguishing AD From MCI

Strategies for Assessing and Preserving Function in ALS

Chapter 30 Delirium and Dementia

Goals of Therapy in Relapsed CLL

Chronic Idiopathic Urticaria

The Chemical Differences Between EPA and DHA.

CDK4/6 Inhibitors in Breast Cancer:

IL-17 Inhibitors in the Management of Psoriatic Disease

Improving Risk Assessment and Early Diagnosis in PAH

Are We Closer to Personalized Medicine in MS?

Overview. Maximizing the Safety of CAR T-Cell Therapy: Prevention, Early Recognition, and Management.

Advances in the Management of Severe and Life-Threatening Chemotoxicity.

Is RA Treatment Addressing the Real Needs of Patients?

Gene Therapy: Past, Present, and Future

Immunotherapy for cSCC

Personalized Therapy in Relapsed or Refractory CLL

Treating to Target in MS

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Introduction to AD. Practical Approaches to the Identification of Alzheimer Disease in Primary Care.

Preventing Clinical Events in PAH

Program Goals Overview Is NEDA a Reasonable Target?

Tackling Schizophrenia With Your Patients

Clinical Genomics in Inflammatory Bowel Disease

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Are We Making Progress in the Management of Huntington Disease?

VOD/SOS: Aligned Education for Patients and the Interprofessional Team

Add-On Therapy to Insulin in T1DM Management

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Essential Updates for PsA: A Complex Disease to Manage

Treating Atypical Hemolytic Uremic Syndrome A Case Discussion

Improving Outcomes in Patients With SSc-ILD

When Good Isn't Good Enough

Program Goals Overview Is NEDA a Reasonable Target?

Clinical Challenges in the Patient With Relapsed Multiple Myeloma

Chapter 25 The Elderly.

Statin Selection in Patients With Pre-Diabetes: Case Considerations

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Importance of Early Diagnosis and Management in SMA

Exploring the Use of Adeno-Associated Virus for Gene Therapy

Navigating the Journey

Understanding the Basics of Dementia-Related Psychosis

The Power of As-Treated Analyses

Presentation transcript:

Modifying Disease Course in Alzheimer's Disease

Program Goals

Alzheimer's Disease Overview

The Importance of Early Diagnosis

Assessing a Patient's Clinical History

Cognitive Testing in Alzheimer's Disease

Genetic and Laboratory Testing

Genetic and Laboratory Testing (cont)

Standard Neuroimaging

Additional Neuroimaging

Is Prevention Possible?

Assessing Risk Factors

AD Prevention Trials: Early-Onset AD

Late-Onset AD Prevention Trial: A4

Late-Onset AD Prevention Trial: TOMORROW

Late-onset AD Prevention Trial: API APOE

Multimodal Interventions

Nutritional Interventions in AD and MCI

Dietary Ketosis in MCI

Medium-Chain Triglycerides in AD

Alzheimer's Disease Cooperative Study: DHA as AD Treatment

The Role of Omega 3s in AD Prevention

B Vitamins and AD

Cholinesterase Inhibitor Add-Ons

Flavinoids and AD

Coffee and AD

Cognitive Intervention

Treating AD Symptoms

Anti-Tau Antibodies

Anti-Hyperglycemic Therapy: SNIFF 120 Study

Anti-Aβ Therapies

Anti-Aβ Therapies (cont)

BACE Inhibitors: Verubecestat

Conclusions

Abbreviations

Abbreviations (cont)